Skip to search formSkip to main contentSkip to account menu

mTOR Inhibitor

Any substance that inhibits mammalian target of rapamycin (mTOR or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)), a serine… 
National Institutes of Health

Related topics

Related topics

1 relation
mTOR Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
Pancreatic ductal adenocarcinoma (PDAC) remains a dismal disease with a poor prognosis and targeted therapies have failed in the… 
2012
2012
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic…
Sequential therapy is a standard strategy used to overcome the limitations of targeted agents in metastatic renal cell carcinoma… 
2012
2012
Development of ATP-competitive mTOR inhibitors.
The mammalian Target of Rapamycin (mTOR)-mediated signaling transduction pathway has been observed to be deregulated in a wide… 
2010
2010
Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
2009
2009
Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus
Everolimus downregulates glucose metabolism–associated genes in preclinical models. Inhibition of glucose metabolism measured by… 
2009
2009
mTOR Inhibitor RAD 001 ( Everolimus ) Has Antiangiogenic / Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Purpose: Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001… 
2009
2009
Photodynamic therapy targets the mTOR signaling network in vitro and in vivo.
Mammalian target of rapamycin (mTOR) is a regulator of cell growth and proliferation and its activity is altered in many human… 
2007
2007
Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin.
2006
2006
Activation of the mTOR signalling pathway is required for pancreatic growth in protease‐inhibitor‐fed mice
Cholecystokinin (CCK)‐induced pancreatic growth in mice involves parallel increases in DNA and protein. The mammalian target of… 
2003
2003
Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)